On Tuesday this large-cap pharma stock gains up to 1.5% after the company entered into a Business Transfer Agreement (BTS). This stock has given 71% returns in six months & 73% returns in one year and the stock closed above the 50-day & 200-day moving averages.
Lupin Ltd
The company has a market capitalisation of Rs. 54,480 Cr making it a Large-cap company. On Tuesday the stock rose up to 1.5%, on the same day the stock reached a new 52-week high of Rs. 1,215.2 and closed 0.14% down at Rs. 1,196.55 on BSE.
According to the BSE filing, Lupin Ltd has entered into a Business Transfer Agreement with Lupin Manufacturing Solutions Limited (LMSL), a wholly-owned subsidiary of the company. To crave out two Active Pharmaceutical Ingredients manufacturing sites situated at Dabhada & Vishakapatnam and select R&D operations, including fermentation, at Lupin Research Park at Pune.
The company’s total revenue grew by 28.5% from Rs. 3,743.8 Cr in Q1 FY23 to Rs. 4,814 Cr in Q1 FY24 and the company reported a net profit of Rs. 453.3 Cr in Q1 FY24 against a loss of Rs. 86.8 Cr in Q1 FY23.
As per the latest shareholding data, Promoters hold 47.06%, FIIs hold 14.99%, DIIs hold 29.43% and the public hold 8.52% stake in the company.
Lupin is a multinational pharmaceutical firm that manufactures branded and generic formulations, biotechnology products, active pharmaceutical ingredients (APIs), and speciality drugs. It holds a global leadership position in the Anti-TB and Cephalosporins segments.
Written by Sheshadri N
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
